EUVIMEDEUVIMED entdecken
Crossref

ADME‐DTI: Augmented Deep Meta Ensemble for Drug–Target Interaction Prediction

Tariq Sha'ban iD, Ahmad M Mustafa iD, Mostafa Z Ali iD, Talal Z Ali iD

Molecular Informatics · 2026-05 · 45 (5)

DOI: 10.1002/minf.70033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Informatics, online erschienen am 30.04.2026. Verfasst von Tariq Sha'ban und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Information Systems, Jordan University of Science and Technology, Irbid, Jordan. Hauptthemen laut MEDLINE: Deep Learning, Drug Discovery, Proteins. Die Arbeit nennt 111 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug–target interaction represents a critical focus area in computational drug discovery and pharmaceutical research. However, the process of identifying and analyzing these interactions is often resource‐intensive, requiring extensive experimentation to evaluate the binding relationships between numerous drugs and their respective targets. This complexity is further compounded by the fact that a drug can inhibit multiple targets, and a target may also bind to various drugs. To address these issues, advanced deep learning models have been introduced as promising tools, offering the ability to accurately predict binding affinity and other bioactivity values to distinguish between potential drug‐target interactions. The proposed model, named the Augmented Deep Meta Ensemble for Drug–Target Interaction (ADME‐DTI), leverages multiple descriptors and fingerprint representations to extract meaningful insights from drug and protein data. These submodels from each representation are then combined with a deep learning architecture along with the metadata of the drug and target entries. The proposed approach has proved competitive performance against state‐of‐the‐art models across diverse datasets and evaluation metrics, as evidenced by key metrics, namely , concordance index, and mean squared error. Specifically, the model achieved mean squared error values of 0.186 (Davis), 0.118 (Kiba), 0.134 (DTC), 0.262 (Metz), 0.300 (ToxCast), and 0.791 (STITCH), all of which are publicly available benchmark datasets commonly used in drug–target interaction prediction tasks. The results highlight the model's effectiveness in reducing prediction errors and improving accuracy. Previous drug–target interaction research often relied on limited, non‐diverse datasets, reducing generalizability. Few studies addressed drug–target interaction prediction as a regression task. Our novel deep learning metamodel integrates multiple models and representations, surpassing benchmarks and delivering greater prediction accuracy across varied datasets and evaluation metrics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep LearningDrug DiscoveryProteinsPharmaceutical PreparationsHumans

Stichwörter der Autor:innen

deep learningdrug‐protein metadatadrug–target interactionmetamodelmulti‐head attention

Substanzen

Pharmaceutical PreparationsProteins

Autor:innen und Institutionen

  • Department of Computer Information Systems, Jordan University of Science and Technology, Irbid, Jordan.
  • Wayne State University, Detroit, Michigan, USA.

ORCID-Profile: Tariq Sha'ban, Ahmad M Mustafa, Mostafa Z Ali, Talal Z Ali

Zitieren

APA

Sha'ban, T., Mustafa, A. M., Ali, M. Z., & Ali, T. Z. (2026). ADME‐DTI: Augmented Deep Meta Ensemble for Drug–Target Interaction Prediction. Molecular Informatics, 45(5). https://doi.org/10.1002/minf.70033

Vancouver

Sha'ban T, Mustafa AM, Ali MZ, Ali TZ. ADME‐DTI: Augmented Deep Meta Ensemble for Drug–Target Interaction Prediction. Molecular Informatics. 2026;45(5). doi:10.1002/minf.70033

BibTeX
@article{Shaban2026,
  author = {Sha'ban, Tariq and Mustafa, Ahmad M and Ali, Mostafa Z and Ali, Talal Z},
  title = {ADME‐DTI: Augmented Deep Meta Ensemble for Drug–Target Interaction Prediction},
  journal = {Molecular Informatics},
  year = {2026},
  volume = {45},
  number = {5},
  doi = {10.1002/minf.70033}
}
Kostenlos starten →